BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
4.310
-0.150 (-3.36%)
At close: Apr 13, 2026, 4:00 PM EDT
4.390
+0.080 (1.86%)
After-hours: Apr 13, 2026, 5:46 PM EDT
BioAtla Revenue
In the year 2025, BioAtla had annual revenue of $2.00M, down -81.82%. BioAtla had revenue of $2.00M in the quarter ending December 31, 2025.
Revenue (ttm)
$2.00M
Revenue Growth
-81.82%
P/S Ratio
3.57
Revenue / Employee
$48,780
Employees
41
Market Cap
7.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.00M | -9.00M | -81.82% |
| Dec 31, 2024 | 11.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 250.00K | -179.00K | -41.72% |
| Dec 31, 2020 | 429.00K | -4.77M | -91.75% |
| Dec 31, 2019 | 5.20M | -5.43M | -51.07% |
| Dec 31, 2018 | 10.63M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBCAB News
- 13 days ago - BioAtla Announces Share Consolidation - GlobeNewsWire
- 13 days ago - BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 6 weeks ago - BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets - GlobeNewsWire
- 3 months ago - BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - GlobeNewsWire
- 5 months ago - BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - GlobeNewsWire
- 5 months ago - BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 5 months ago - BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas - GlobeNewsWire
- 5 months ago - BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 - GlobeNewsWire